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Abstract 
Background: There is an urgent need to identify molecular signatures in small cell lung cancer (SCLC) that may 
select patients who are likely to respond to molecularly targeted therapies. In this study, we investigate the feasibility 
of undertaking focused molecular analyses on routine diagnostic biopsies in patients with SCLC.
Methods: A series of histopathologically confirmed formalin-fixed, paraffin-embedded SCLC specimens were ana-
lysed for epidermal growth factor receptors (EGFR), KRAS, NRAS and BRAF mutations, ALK gene rearrangements and 
MET amplification. EGFR and KRAS mutation testing was evaluated using real time polymerase chain reaction (RT-PCR 
cobas®), BRAF and NRAS mutations using multiplex PCR and capillary electrophoresis-single strand conformation 
analysis, and ALK and MET aberrations with fluorescent in situ hybridization. All genetic aberrations detected were 
validated independently.
Results: A total of 105 patients diagnosed with SCLC between July 1990 and September 2006 were included. 60 
(57 %) patients had suitable tumour tissue for molecular testing. 25 patients were successfully evaluated for all six 
pre-defined molecular aberrations. Eleven patients failed all molecular analysis. No mutations in EGFR, KRAS and NRAS 
were detected, and no ALK gene rearrangements or MET gene amplifications were identified. A V600E substitution in 
BRAF was detected in a Caucasian male smoker diagnosed with SCLC with squamoid and glandular features.
Conclusion: The paucity of patients with sufficient tumour tissue, quality of DNA extracted and low frequency of 
aberrations detected indicate that alternative molecular characterisation approaches are necessary, such as the use of 
circulating plasma DNA in patients with SCLC.
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Background
Lung cancer is the leading cause of cancer-related deaths 
globally [1]. Small cell lung cancer (SCLC) is an aggres-
sive neuroendocrine subtype of lung cancer that repre-
sents 13–15  % of all lung cancers [2]. SCLC is strongly 
linked to smoking and is characterised by rapid doubling 
time with early onset of dissemination and frequently 
presents (60–70 %) with advanced disease extensive stage 
(ED) [3]. Extensive stage disease SCLC has a median 
overall survival of 7–12  months [4]. The mainstay of 
treatment remains platinum-based doublet chemo-
therapy and despite benefits from prophylactic cranial 
radiation (PCI) and thoracic radiotherapy systemic 
treatments have not changed over the last few decades 
[5–7]. SCLC demonstrates impressive response rates to 
first-line chemotherapy but relapse with chemotherapy 
resistant disease and death frequently shortly follows [8]. 
There thus remains an urgent clinical need to develop 
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novel therapeutic strategies that impact on this common, 
aggressive disease.
Numerous unselected phase II clinical trials have eval-
uated molecularly targeted therapies in first-line, main-
tenance and second-line treatment of SCLC [3, 9–12]. 
These have included agents that regulate a plethora of 
cellular processes including angiogenesis, cell signaling, 
DNA repair pathways and apoptosis. No targeted ther-
apy has demonstrated efficacy is SCLC and no targeted 
treatments have been licenced for use in this aggressive 
disease. Molecular aberrations have been identified in 
patients with non-small cell lung cancer (NSCLC) over 
the past 10 years and revolutionised treatment strategies 
[13]. Until recently little was known about the molecu-
lar profile of SCLC. Recent studies have begun to unravel 
molecular aberrations present in patients with SCLC [2, 
14–18]. Two studies used targeted gene panels and iden-
tified genetic aberrations in 15 % (9 gene panel) and 6.2 % 
(6 gene panel) of patients with SCLC [2, 15]. The most 
common aberrations within the targeted studies were 
phosphatidylinositol-3-kinase catalytic subunit alpha 
(PI3KCA 15  %) and MET (4.4  %) [2, 15]. A more com-
prehensive analysis of 236 cancer genes using next gen-
eration sequencing demonstrated all 98 patients to have 
at least one genomic alteration [14]. The most common 
aberrations were rapamycin-insensitive companion of 
mTOR (RICTOR; 10 %), stem cell factor receptor tyrosine 
kinase (KIT; 7 %), PI3KCA (6 %) epidermal growth factor 
receptor (EGFR; 5  %), phosphatase and tensin homolog 
(PTEN; 5 %) and KRAS (5 %) [14]. The identification and 
validation of molecular aberrations within SCLC may 
potentially facilitate the development of effective targeted 
therapies for the treatment of SCLC.
We investigated the feasibility of performing molecular 
studies on biopsy material surplus to the SCLC diagnos-
tic algorithm. We assessed the mutational status of sev-
eral oncogenes (EGFR, BRAF, KRAS and NRAS), together 
with ALK gene rearrangements and MET gene amplifica-
tion in patients with SCLC.
Methods
Patient cohort
One hundred and five patients were diagnosed with 
SCLC between 1st July 1990 and 1st September 2006 
at the Royal Marsden Hospital. Seventy-two patients 
had formalin-fixed, paraffin-embedded (FFPE) blocks 
of which 60 were deemed to have enough tissue for 
molecular analysis (Fig.  1). Patients included within the 
study had a biopsy-proven diagnosis of SCLC and were 
≥18 years old. Patients were excluded if they only had a 
cytological or clinical diagnosis of SCLC. Informed con-
sent for use of tissue for research was obtained if the 
patient was still alive and diagnosed after September 1st 
2006, according to the Human Tissue Act. The study was 
approved by both the Research Ethics Committee (11/
SC/0073) and Local Committee for Clinical Research 
(CCR 3428). All samples were routinely fixed. The hospi-
tals electronic patient records were used to collect clini-
cal characteristics including age, sex, smoking history, 
performance status (PS), stage (VALG), type of treatment 
and first-line chemotherapy regime received (Table  1). 
Smoking status for patients was defined at diagnosis. 
These were divided into current smokers and ex-smokers 
depending on their smoking status at diagnosis.
SCLC diagnosis was not validated for the purposes 
of this study. It had previously been made by patholo-
gists at the Royal Marsden Hospital according to the 
2004 World Health Organisation classification based 
on morphology (uniform round to spindle-shaped small 
cells, sparse cytoplasm, high mitotic index and necrotic 
areas). Presence of cancer cells within biopsies was con-
firmed by a histopathologist (AW) prior to molecular 
analysis.
Molecular characterisation
DNA preparation
For all suitable tumour specimens, 5 and 2  μm tissue 
section slides were prepared. The 5 μm slides were used 
for DNA extraction and subsequent analysis for EGFR, 
KRAS, BRAF and NRAS while the 2  μm slides were 
used directly for fluorescent in situ hybridisation (FISH) 
analysis of ALK and MET. DNA extraction was done 
using Roche cobas® DNA sample preparation kit (Roche 
Molecular Systems Incorporation, Branchburg, New Jer-
sey, USA).
Fig. 1 Patient cohort. One hundred and five patients were diag-
nosed with SCLC between the 1st July 1990 and 1st September 2006. 
Thirty-three patients identified had no tissue blocks available and a 
further 12 patients had insufficient tissue for molecular analysis. Sixty 
patients with sufficient tissue for molecular analysis were included in 
the study
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EGFR mutation
EGFR mutation analysis was performed on extracted 
DNA using Roche cobas® EGFR Mutation test (Roche 
Molecular Systems Incorporation, Branchburg, New 
Jersey, USA). It is a CE-marked allele-specific real-time 
PCR assay designed to detect mutations in exons 18, 19, 
20, and 21 of the EGFR gene in FFPE tissue specimens. 
The EGFR test is a 3-tube assay designed to detect G719X 
(G719A, G719C, and G719S), in exon 18, deletions and 
complex mutations in exon 19, S768I, T790M, and inser-
tions in exon 20, and L858R in exon 21. Mutation detec-
tion is achieved through PCR analysis with the cobas® 
4800 System (Roche Molecular Systems Incorporation, 
Branchburg, New Jersey, USA) with automated result 
interpretation software. The results were presented in the 
form of positive, negative, invalid or failed.
KRAS mutation
KRAS mutation analysis was performed on extracted 
DNA by the cobas® KRAS Mutation test (Roche Molec-
ular Systems Incorporation, Branchburg, New Jersey, 
USA). It is a CE-marked real-time TaqMelt PCR assay 
designed to detect somatic mutations in codons 12, 13 
(exon 2) and 61 (exon 3) of the KRAS gene. Mutations 
are detected by melting curve analysis, using the cobas® 
4800 System (Roche Molecular Systems Incorporation, 
Branchburg, New Jersey, USA) with automated result 
interpretation software. The results were presented in the 
form of positive, negative, invalid or failed.
BRAF and NRAS mutation
BRAF and NRAS mutation analysis was performed on 
extracted DNA by multiplex PCR and capillary electro-
phoresis-single strand conformation analysis (CE-SSCA) 
using an in-house procedure. PCR was done using the 
2720 Thermal Cycler (Applied Biosystems®, Foster City, 
USA) and the BRAF/NRAS mutational analysis was done 
using the ABI 3130XL Genetic Analyzer (Applied Biosys-
tems®, Foster City, USA). For BRAF, a V600E mutation 
will result in a characteristic pattern in the CE-SSCA at 
all different temperatures and therefore requires no fur-
ther confirmation by sequencing. For any unclear results, 
Direct DNA Sanger sequencing was performed for con-
firmation. For NRAS, any mobility shift identified by 
CE-SSCA in codon 61 or codon 12/13 was confirmed by 
Direct DNA Sanger sequencing. This was done using the 
9800 fast thermal cycler (Applied Biosystems®, Foster 
City, USA) and the ABI 3500 Genetic analyzer (Applied 
Biosystems®, Foster City, USA). Sequencing data was 
analysed using Mutation Surveyor software.
ALK rearrangements
FISH analysis was directly performed on the 2 μm slides. 
Vysis LSI ALK Dual Colour Break Apart FISH Probe 
(Abbott Molecular Inc., Des Plaines, IL, USA) was used 
for ALK testing (Abbott Vysis ALK Break Apart FISH 
Probe Kit, Abbott laboratories, Illinois, USA). Results 
were analysed using Zeiss AxioImager Z2 Fluorescence 
Table 1 Patient demographics
ECOG eastern cooperative oncology group, PS performance status, LD limited 
disease, ED extensive disease, ACE adriamycin, cyclophosphamide and 
etoposide, MVP mitomycin C, vinblastine and cisplatin
N = 60 %
Mean age 65.9
 Range 45–84
Gender
 Male 29 48.3
 Female 31 51.7
Smoking history
 Current smoker 44 73.3
 Past smoker 16 26.7
ECOG PS
 0 5 8.3
 1 15 25
 2 20 33.3
 3 19 31.7
 4 1 1.7
Stage
 LD 33 55
 ED 27 45
Histology
 Small cell carcinoma 59 98.3
 Combined small cell carcinoma 1 1.7
Treatment
 Chemotherapy 51 85
 Refused 3 5
 Not fit 3 5
 RT/surgery 3 5
First-line chemotherapy
 Carbo/etoposide 13 21.7
 ACE 13 21.7
 MVP 13 21.7
 Etoposide 5 8.3
 Cisplatin/etoposide 2 3.3
 Other/no chemotherapy 5/9 8.3/15
Number of cycles of treatment
 1–3 cycles 16 31.4
 4–6 cycles 35 68.6
Response to first-line treatment
 Complete response 4 7.8
 Partial response 29 56.9
 Stable disease 10 19.6
 Progressive disease 8 15.7
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microscope (Carl Zeiss Microscopy, Madrid, Spain). 
Reporting of ALK FISH test results was done according 
to the FISH probe manufacturers (Abbott laboratories, 
Illinois, USA) with the normal cut-off level of 15  % in 
FFPE tissue specimen.
MET amplification
For MET amplification detection by FISH, KREATECH 
Poseidon™ Repeat Free™ C-MET (7q31) and SE7 probe 
(KREATECH diagnostics, Amsterdam, Holland) was 
used. Results were analysed using Zeiss AxioImager 
Z2 Fluorescence microscope (Carl Zeiss Microscopy, 
Madrid, Spain). Reporting of MET FISH test results has 
no standardized procedure as MET FISH is not used as 
a diagnostic tool. In our study, the reporting was done by 
using 10 % as a cut-off similar to ALK amplification [19]. 
If 10 % or more of the cells show a ratio of R: G >2, then 
the sample is considered MET positive. All samples with 
more than 5 % MET positivity were re-scored using the 
PathVysion scoring system, similar to the approved HER2 
amplification scoring system in breast cancer. The Path-
Vysion scoring system was done by determining the ratio 
between the red signals and the green signals (adding the 
total number of reds in the 20 cells (R) and the total num-
ber of greens in 20 cells (G), then dividing R/G and get-
ting a ratio). If the ratio is <2, the sample does not show 
MET amplification and if the ratio is ≥2, then the sam-
ple shows MET amplification (as per PathVysion HER-2 
DNA Probe Kit, Abbott laboratories, Illinois, USA).
Results
Patient characteristics
Between 1st July 1990 and 1st September 2006 FFPE 
blocks for 60 patients were assessed for genomic aber-
rations. The patient characteristics are shown in Table 1. 
The mean age (range) was 65.9 (45–84) years. Twenty-
nine patients (48.3  %) diagnosed with SCLC were male 
and 31 patients (51.7 %) were female. Forty-four patients 
(73.3  %) were current smokers and 16 patients (26.7  %) 
were past smokers. There were no never smokers identi-
fied within this study. Forty patients (66.7 %) were East-
ern Cooperative Oncology Group (ECOG) PS 0–2. A 
total of 59 patients (98.3 %) were diagnosed with SCLC 
and one patient (1.7  %) was diagnosed with combined 
SCLC. Those biopsies in which immunohistochem-
istry had been performed historically were recorded 
from our electronic patient records (Table  2). Twenty-
seven patients (45 %) had ED SCLC at diagnosis and 51 
patients (85 %) received first-line chemotherapy. Thirty-
five patients (68.6 %) received 4–6 cycles of chemother-
apy whist 16 patients (31.4  %) received 1–3 cycles. The 
response rates to first-line chemotherapy were complete 
response (4 patients 7.8 %), partial response (29 patients 
56.9 %), stable disease (10 patients 19.6 %) and progres-
sive disease (8 patients 15.7 %).
Table 2 Results of  immunohistochemistry analysis (his-
torical)
Immunohistochemical test N = 60
TTF1
 Positive 5
 Negative 0
 Not available 55
CD56
 Positive 4
 Negative 1
 Not available 55
CAM5.2
 Positive 33
 Negative 3
 Not available 24
Cytokeratin 7
 Positive 2
 Negative 0
 Not available 58
Chromogranin A
 Positive 15
 Negative 13
 Not available 32
NSE
 Positive 14
 Negative 5
 Not available 41
Synaptophysin
 Positive 21
 Negative 12
 Not available 27
CD45
 Positive 0
 Negative 31
 Not available 29
MNF116
 Positive 27
 Negative 4
 Not available 29
EMA
 Positive 18
 Negative 8
 Not available 34
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Molecular characterisation
Sample quality
Entry into the study was determined by the presence 
of cancer cells (morphological analysis) and sufficient 
FFPE tissue for molecular analysis (determined by 
AW). Samples were not pre-assessed for their quality 
and yield of DNA prior to study analysis. Therefore a 
number of samples had insufficient DNA (quantity and/
or quality) for molecular analysis (successful analy-
sis summarised in Table 3). Twenty-five cases (41.7 %) 
were successfully analysed for all mutations (EGFR, 
KRAS, BRAF and NRAS), gene rearrangement (ALK) 
and amplification (MET) (Table  3). There was marked 
variation in the DNA concentration of these samples 
(0.2–57.3  ng/µl; mean 12.1  ng/µl). Thirty cases (50  %) 
were successfully analysed for all mutations (EGFR, 
KRAS, BRAF and NRAS) (Table 3). These samples also 
showed marked variation in extracted DNA concen-
tration (1.0–57.3  ng/µl; mean 11.0  ng/µl). Finally, 11 
cases (18.3 %) provided no interpretable results for all 
mutations with DNA concentrations ranging from 0.20 
to 31.7 ng/µl; mean 9.8 ng/µl) (Table 3). FISH analysis 
was successful for ALK rearrangement and MET ampli-
fication in 58 (96.7  %) and 42 (70  %) of SCLC cases 
(Table 3).
Genomic aberrations
We detected a single genetic aberration within the 60 
cases of SCLC analysed. This was within the BRAF gene. 
The mutation was a single amino acid substitution of 
valine (V) to glutamic acid (E) at position 600 (V600E 
mutation) (Fig. 2; Table 3). In cases that were suitable for 
analysis there were no mutations identified within the 
EGFR (31 cases), KRAS (35 cases) and NRAS (37 cases) 
genes (Table  3). In addition, there were no cases identi-
fied with ALK rearrangements (58 cases) or MET ampli-
fication (42 cases) (Table  3). The patient identified with 
a BRAF V600E substitution was a 55 year-old Caucasian 
current smoker. He was diagnosed, radiologically, with 
a T2N0M0 lung cancer and underwent lobectomy. His 
postoperative histology demonstrated combined small 
cell carcinoma with squamoid and glandular features. He 
received no adjuvant therapy. Six months later he pre-
sented with recurrent LD SCLC for which he received 
radical chemoradiotherapy (four cycles of Carboplatin/
Etoposide and radiotherapy 36  Gy in 12 fractions) and 
PCI with good response. He died suddenly 9 months later.
Immunohistochemical analysis
Repeat immunohistiochemistry (IHC) was not per-
formed on patient samples in this study. Results for the 
42 patients who had historical IHC performed were 
collated from our electronic patient records system 
(Table 2). Five out of five patients (100 %) stained positive 
for TTF-1 and 15 out 28 patients (53.6 %) stained posi-
tive for Chromagranin A (Table 2). CD56 and synaptoph-
sin were expressed in 4 out of 5 (80 %) and 21 out of 33 
(63.6 %) respectively (Table 2).
Discussion
In the present study, the mutation rate of a 4-gene panel 
(EGFR, NRAS, KRAS and BRAF), ALK gene rearrange-
ments and MET amplification was evaluated in patients 
with SCLC who had enough tissue for molecular analy-
sis after diagnosis between the 1st July 1990 and 1st Sep-
tember 2006 (Fig. 1). This study explores the feasibility of 
performing focused molecular analysis within standard 
diagnostic algorithms in SCLC.
Sixty (57 %) patients of the 105 diagnosed with SCLC in 
the study period had sufficient tissue for genomic analysis 
and 45 patients (33 patients no tissue block; 12 patients 
insufficient tissue) lacked sufficient tissue for molecular 
analysis (Fig. 1). Twenty-five (42 %) patients were success-
fully analysed for all molecular aberrations tested (EGFR, 
NRAS, KRAS and BRAF mutations; ALK rearrangements; 
MET amplification). A single mutation (1.7 % of patients) 
within BRAF was identified. The mutation was a single 
amino acid substitution of valine (V) to glutamic acid (E) 
at position 600 (V600E mutation). This was detected in a 
Caucasian male smoker diagnosed with SCLC with squa-
moid and glandular features. It is conceivable that the 
mutation was within the squamoid component although 
this would still represent a rare event within NSCLC [20].
Table 3 Results of successful molecular analysis
Gene
BRAF
 Aberration 1 (BRAF V600E)
 No aberration 46
EGFR
 Aberration 0
 No aberration 31
KRAS
 Aberration 0
 No aberration 35
NRAS
 Aberration 0
 No aberration 37
ALK
 Rearrangement 0
 No rearrangement 58
MET
 Amplification 0
 No amplification 42
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The failure rates observed may be, in part, due to the 
paucity of tissue available from routine diagnostic biop-
sies. Routinely the diagnosis of SCLC is made without 
immunohistochemistry analysis. However in this study 
42 patients had further immunostaining performed 
due to diagnostic uncertainty (Table 2). Consistent with 
other studies these confirmed high positivity for TTF-1, 
cytokeratin, CAM, CD56, NSE, chromogranin, synop-
tophysin and EMA [21, 22]. These extra analyses com-
pound further the paucity of patient tissue available for 
molecular analysis.
The quality of extracted DNA from tissue biopsies 
may account for the failure rates observed. Thirty (50 %) 
of the 60 patients evaluated were successfully analysed 
for EGFR, NRAS, KRAS and BRAF mutations. The con-
centration of extracted DNA in these cases was 1.0–
57.3 ng/µl (mean 11.0 ng/µl). Interestingly, in the eleven 
(18.3  %) patients that failed molecular analysis for 
EGFR, KRAS, BRAF and NRAS mutations the extracted 
DNA concentrations (0.2–31.7  ng/µl; mean 9.8  ng/µl) 
did not differ from those patients successfully analysed 
for molecular aberrations. This suggests that DNA qual-
ity as opposed to DNA quantity is critically important 
for success of the molecular analysis performed within 
this study.
Two recent studies used focused gene panels to identify 
molecular aberrations in SCLC patients [2, 15]. The most 
common alterations identified were in PIK3CA (5 % muta-
tions and 10 % amplifications) and MET (4.4 % mutation) 
[2, 15]. Similar to our own study the incidence of EGFR 
(1.8 % and 1.7 %), NRAS (0 %) and KRAS (0 % and 1.7 %) 
mutations, ALK rearrangements (0 %) and MET amplifica-
tions (1.7 %) were low or not seen [2, 15]. In contrast to 
our own there were no cases (173 patients) of SCLC with 
BRAF mutations identified in these studies. These stud-
ies along with our own study have attempted to identify 
potential molecular alterations that could stratify patients 
to targeted therapies. However, the alterations identified 
were of low frequency (1.8, 6.1 and 15 % of patients ana-
lysed) and alternative approaches should be sought.
Recent advances in cancer genome sequencing tech-
nologies have led to more comprehensive analysis of 
SCLC through whole-exome sequencing and targeted 
sequencing [14, 16–18]. These studies have shown high 
prevalence of inactivating mutations within TP53 and Rb 
tumour suppressor genes, amplification of MYC family 
members and mutation of histone modifiers (CREBBP 
and EP300) [14, 16–18]. Ross and colleagues identified 
53 % of SCLC cases with at least a single actionable alter-
ation with the potential to personalise therapy [14]. These 
Fig. 2 Positive BRAF mutation detected by capillary electrophoresis-single strand conformation analysis. Capillary electrophoresis-single strand 
conformation analysis demonstrates V600E BRAF mutation in patient sample. Positive and negative controls are shown. Black arrow corresponds to 
extra peak representing the V600E BRAF mutation
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next generation sequencing approaches are likely to be 
more fruitful than focused approaches in driving transla-
tional studies within SCLC.
Our study demonstrates the limitations of using tra-
ditional diagnostic biopsies for molecular analysis in 
SCLC. In addition to difficulties with tissue availabil-
ity, this and other focused studies using pre-defined 
gene panels have identified low frequency of action-
able mutations in patients with SCLC. Moreover, 
small tumour biopsies contain relatively few tumour 
cells limiting our understanding of the heterogeneity 
of SCLC. We propose a model for future translational 
studies in SCLC whereby patients undergo tumour 
biopsies at diagnosis to obtain sufficient tissue for 
molecular analysis (Fig.  3). Blood samples should also 
be collected for isolation of circulating tumour cells 
(CTCs) and circulating plasma DNA (cpDNA) (Fig. 3). 
Molecular analysis of these samples should be used to 
stratify patients to treatment with targeted therapies 
within clinical studies (Fig. 3). In addition, novel aber-
rations should drive translational studies and drug dis-
covery efforts to identify novel therapeutic strategies 
for the treatment of SCLC (Fig.  3). This approach is 
further supported by a recent phase II basket trial that 
included patients with SCLC. The study failed to dem-
onstrate clinical benefit with targeted therapies based 
on limited molecular profiling from a single tumour 
biopsy [23]. We believe this approach will increase our 
understanding of SCLC, and with the identification 
and validation of molecular signatures associated with 
SCLC we may finally see clinical benefit from existing 
targeted therapies, and see a new wave of therapies 
developed for the treatment of SCLC.
Conclusions
This study demonstrates the limitations of performing 
focused molecular analysis on SCLC biopsies after diag-
nostic investigations are complete. The paucity of tissue 
available (57 % of patients), the quality of DNA extracted 
and the low frequency of aberrations detected (1.7 % of 
patients) means alternative approaches should be sought. 
To further understand the biology of SCLC and identify 
molecular aberrations in patients with SCLC that can be 
incorporated into treatment algorithms and used to iden-
tify novel therapeutic strategies for treatment of SCLC 
we need to focus on obtaining adequate tissue to carry 
out these studies. This may be through obtaining more 
tissue at diagnosis and exploring alternative approaches 
including CTCs and cpDNA. In addition we should move 
from focused gene analysis with low frequency molecu-
lar changes to wider exome-sequencing and targeted 
sequencing. These approaches will allow sequential anal-
ysis of genomic aberrations that will increase our under-
standing of the molecular basis of SCLC and help further 
identify patients that are most likely to respond to tar-
geted therapies.
Fig. 3 Proposed model for molecular analysis of SCLC and incorporation into translational studies. Patients should undergo a tumour biopsy to 
obtain sufficient tissue for molecular analysis alongside collection of blood specimens to isolate circulating plasma DNA (cpDNA) and circulating 
tumour cells (CTCs). Molecular analysis of these samples should be used for translational studies. These may be clinical studies in which patients 
identified to have actionable aberrations enter clinical studies in which there treatment (T) is determined by sequencing data. These patients 
should have sequential genomic analysis through cpDNA and CTCs to identify further molecular aberrations (X) that may confer resistance and 
determine further treatment (A, B, C and D) strategies. These molecular studies are also likely to identify novel or non-actionable changes within 
SCLC that should be further studied to determine their functional role and potential as novel therapeutic targets for the treatment of SCLC
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